Go back to News
NEWS
Daniel Reis appointed as new partner in Intellectual Property at Gómez-Acebo & Pombo in Lisbon
3 February, 2026
Gómez-Acebo & Pombo (“GA_P”) has appointed Daniel Reis as a new partner in the Intellectual Property and Technology practice at its Lisbon office.
Daniel Reis specialises in the telecommunications sector and has extensive experience advising on data protection, privacy and cybersecurity matters. He is recognised as one of the leading professionals in the TMT area in Portugal by the prestigious legal directories Chambers & Partners—where he is ranked Band 1—and The Legal 500, which distinguishes him as a Leading Individual.
Daniel Reis will join the Intellectual Property and Technology team led by Sofía Martínez-Almeida, further strengthening the practice following the incorporation of Rais Amils last year, as well as the firm’s practice in Portugal, which Daniel will lead and which is focused on strategic growth.
Lawyer mentioned
Daniel Reis – Partner
Sofía Martínez-Almeida – Partner
See all lawyers
See less lawyers
Category
Press Release
Areas and sectors
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
¡NEW! 
PUBLICATION
One week ago
The long arm of the Unified Patent Court based on the "event giving rise to the infringement" and considerations on the application of lex loci protectionis
This paper analyses the decision of the Mannheim Local Division of 2 October 2025, where the Unified Patent Court (UPC) justifies its jurisdiction on the basis of shipment of products from a UPC territory by company listed as authorized representative in the EC and UK markets as event giving rise to damage. Furthermore, although the applicable law with regard to the infringement of the European patent validated in States that are not party to the Agreement on a Unified Patent Court is the national law of those States, with regard to the scope of patent protection, the UPC imposes on the defendant—unduly—the burden of proving the specifics of national law.
One week ago 
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICATION
29 Jan, 2026
On Call Protocol for the Alimentaria and Hostelco 2026 Trade Fairs
In preparation for the Alimentaria and Hostelco 2026 trade fairs, the Commercial Section of the Barcelona First Instance Court has approved a rapid response protocol to deal promptly with any potential conflicts relating to intellectual and industrial property rights (patents,trademarks, designs, and copyright), as well as trade secrets and unfair competition issues that may arise during these events.
29 Jan, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026
PUBLICATION
19 Dec, 2025
Requirements for lawful descriptive use of a third-party trade mark with reputation
In Judgment 1505/2025, the Supreme Court analyses the use of the term 'Donut' by a competitor that markets ring-shaped pastry under another trade mark. Although previous instances considered the use to be merely descriptive, the Supreme Court rejects this on the grounds that it is a reputed trade mark, which triggers enhanced protection. This protection requires avoiding any unfair use of the prestige or distinctive character of the trade mark. The court concludes that the use made was not fair and may involve parasitism and dilution.
19 Dec, 2025
PUBLICATION
18 Dec, 2025
Prepared for the 2026 Mobile World Congress?
The protocol, agreed jointly by the Courts of Barcelona and Alicante, provides for priority handling of applications for pre-trial examination and fact-finding orders, as well as applications for interim measures —with or without a hearing— in matters relating to patents and technological innovations, industrial designs, trademarks and copyright, as well as antitrust, unfair competition and unlawful advertising, when linked to products or presentation, display, promotion, offering or sale activities connected to MWC 2026.
18 Dec, 2025
PUBLICATION
09 Dec, 2025
Pharma & Healthcare No. 46
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
09 Dec, 2025